168 related articles for article (PubMed ID: 37079967)
21. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies.
Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A
Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060
[TBL] [Abstract][Full Text] [Related]
22. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
24. Discovery of phthalazino[1,2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway.
Liu Q; Zhang B; Wang Y; Wang X; Gou S
Eur J Med Chem; 2022 Feb; 229():114058. PubMed ID: 34954595
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
29. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.
Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D
Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 1,3-Disubstituted 2,5-Diketopiperazine Derivatives as Potent Class I HDACs Inhibitors.
Gong G; Qi J; Lv Y; Dong S; Cao C; Li D; Zhao R; Li Z; Chen X
Chem Pharm Bull (Tokyo); 2020; 68(5):466-472. PubMed ID: 32378544
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities.
Chu JC; Tseng HJ; Lee SB; Hsu KC; Hsin LW; Liang RH; Lin TE; Gao NC; Chen LC; Lu WH; Wang AH; Huang WJ
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2212326. PubMed ID: 37190931
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and histone deacetylase inhibition study of novel 4-(2-aminoethyl) phenol derivatives.
Podili R; Mishra KMA; Akkewar AS; Kumar S; Rayala VVSPK; Kulhari U; Sahu BD; P R; Sethi KK
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23591. PubMed ID: 38037273
[TBL] [Abstract][Full Text] [Related]
34. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors.
Zhu F; Meng X; Liang H; Sheng C; Dong G; Liu D; Wu S
Bioorg Chem; 2022 May; 122():105702. PubMed ID: 35286923
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
Chen X; Zhao S; Li H; Wang X; Geng A; Cui H; Lu T; Chen Y; Zhu Y
Eur J Med Chem; 2019 Apr; 168():110-122. PubMed ID: 30802729
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.
Zhu Y; Ran T; Chen X; Niu J; Zhao S; Lu T; Tang W
Chem Pharm Bull (Tokyo); 2016; 64(8):1136-41. PubMed ID: 27477652
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton.
Sun S; Zhao W; Li Y; Chi Z; Fang X; Wang Q; Han Z; Luan Y
Bioorg Chem; 2021 Mar; 108():104652. PubMed ID: 33497873
[TBL] [Abstract][Full Text] [Related]
39. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors.
Dong Y; Hu H; Sun Y; Qin M; Gong P; Hou Y; Zhao Y
Bioorg Med Chem Lett; 2020 Dec; 30(23):127610. PubMed ID: 33045329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
